A Phase 2, Randomized, Triple-Blind, Placebo-Controlled, Short-Term, Dose-Response Study to Examine the Effect on Glucose Control and Safety and Tolerability of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus

Registration

Registration

NCT00044694

Study type

INTERVENTIONAL

Allocation

RANDOMIZED

Phase

PHASE2

Masking

DOUBLE

Status

COMPLETED

Enrollment

156

Start

2002-08

Primary completion

2003-05

Lead sponsor

AstraZeneca

Conditions

Diabetes Mellitus, Non-Insulin-Dependent

Interventions

DRUG:Placebo 0.01 mL; DRUG:Placebo 0.02 mL; DRUG:Placebo 0.03 mL; DRUG:Placebo 0.04 mL; DRUG:AC2993 2.5 mcg; DRUG:AC2993 5.0 mcg; DRUG:AC2993 7.5 mcg; DRUG:AC2993 10.0 mcg

Results posted

FALSE

Registered primary outcomes

• Change in HbA1c (glycosylated hemoglobin) from Baseline to Day 28 [Baseline (Day 1) to Day 28]